Physician profile
Ann Kuo
NPI 1790030005
$936.60
in general payments reported to CMS, 2019-2025
17 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $133 · 2021: $22.56 · 2022: $81.77 · 2024: $212 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $319.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $165.10 | 2019 | |
| Glaxosmithkline, LLC. | $150.07 | 2019-2025 | Ojjaara, Blenrep |
| Pfizer INC. | $105.58 | 2020 | |
| Janssen Pharmaceuticals, INC | $90.37 | 2019 | |
| Novartis Pharmaceuticals Corporation | $87.95 | 2021-2025 | |
| Seagen INC. | $65.02 | 2022 | |
| Gilead Sciences, INC. | $64.39 | 2025 | Trodelvy |
| Sobi, INC | $35.89 | 2024 | |
| Merck Sharp & Dohme LLC | $31.97 | 2019 | |
| Daiichi Sankyo INC. | $30.49 | 2019-2024 | Vanflyta |
| Actelion Pharmaceuticals US, INC. | $21.24 | 2019 | |
| Cranial Technologies, INC | $16.75 | 2022 | |
| Alexion Pharmaceuticals, INC. | $15.19 | 2019 | |
| Sumitomo Pharma America, INC. | $15.14 | 2024 | Orgovyx |
| Teva Pharmaceuticals USA, INC. | $14.49 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14.48 | 2019 | |
| Astellas Pharma US INC | $12.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Kuo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.